...
search icon
acad-img

ACADIA Pharmaceuticals Inc, Common Stock

ACAD

NSQ

$18.4

+$0.13

(0.71%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.06B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
23.4231
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.47M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.38
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$14.15 L
$26.83 H
$18.4

About ACADIA Pharmaceuticals Inc, Common Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameACADSectorS&P500
1-Week Return2.85%3.54%-0.58%
1-Month Return10.25%7.51%1.89%
3-Month Return24.83%-0.85%3.24%
6-Month Return-1.87%-1.67%10.09%
1-Year Return-33.19%5.2%22.09%
3-Year Return-16.78%13.08%35.68%
5-Year Return-55.72%44.4%83.47%
10-Year Return-41.06%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue339.08M441.75M484.14M517.24M726.44M[{"date":"2019-12-31","value":46.68,"profit":true},{"date":"2020-12-31","value":60.81,"profit":true},{"date":"2021-12-31","value":66.65,"profit":true},{"date":"2022-12-31","value":71.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue19.60M20.55M19.14M10.17M45.73M[{"date":"2019-12-31","value":42.85,"profit":true},{"date":"2020-12-31","value":44.94,"profit":true},{"date":"2021-12-31","value":41.86,"profit":true},{"date":"2022-12-31","value":22.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit319.48M421.20M465.00M507.07M680.71M[{"date":"2019-12-31","value":46.93,"profit":true},{"date":"2020-12-31","value":61.88,"profit":true},{"date":"2021-12-31","value":68.31,"profit":true},{"date":"2022-12-31","value":74.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin94.22%95.35%96.05%98.03%93.70%[{"date":"2019-12-31","value":96.11,"profit":true},{"date":"2020-12-31","value":97.26,"profit":true},{"date":"2021-12-31","value":97.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.58,"profit":true}]
Operating Expenses566.02M707.79M635.44M730.66M754.09M[{"date":"2019-12-31","value":75.06,"profit":true},{"date":"2020-12-31","value":93.86,"profit":true},{"date":"2021-12-31","value":84.27,"profit":true},{"date":"2022-12-31","value":96.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(246.54M)(286.59M)(170.44M)(223.60M)(73.38M)[{"date":"2019-12-31","value":-24654500000,"profit":false},{"date":"2020-12-31","value":-28658600000,"profit":false},{"date":"2021-12-31","value":-17043900000,"profit":false},{"date":"2022-12-31","value":-22359600000,"profit":false},{"date":"2023-12-31","value":-7337900000,"profit":false}]
Total Non-Operating Income/Expense23.33M12.22M3.51M16.76M39.58M[{"date":"2019-12-31","value":58.94,"profit":true},{"date":"2020-12-31","value":30.88,"profit":true},{"date":"2021-12-31","value":8.87,"profit":true},{"date":"2022-12-31","value":42.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(234.38M)(280.97M)(167.52M)(213.44M)(51.04M)[{"date":"2019-12-31","value":-23438300000,"profit":false},{"date":"2020-12-31","value":-28097300000,"profit":false},{"date":"2021-12-31","value":-16751900000,"profit":false},{"date":"2022-12-31","value":-21344400000,"profit":false},{"date":"2023-12-31","value":-5103600000,"profit":false}]
Income Taxes876.00K611.00K351.00K2.53M10.25M[{"date":"2019-12-31","value":8.55,"profit":true},{"date":"2020-12-31","value":5.96,"profit":true},{"date":"2021-12-31","value":3.42,"profit":true},{"date":"2022-12-31","value":24.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(235.26M)(281.58M)(167.87M)(215.97M)(61.29M)[{"date":"2019-12-31","value":-23525900000,"profit":false},{"date":"2020-12-31","value":-28158400000,"profit":false},{"date":"2021-12-31","value":-16787000000,"profit":false},{"date":"2022-12-31","value":-21597500000,"profit":false},{"date":"2023-12-31","value":-6128600000,"profit":false}]
Income From Continuous Operations(235.26M)(281.58M)(167.87M)(215.97M)(61.29M)[{"date":"2019-12-31","value":-23525900000,"profit":false},{"date":"2020-12-31","value":-28158400000,"profit":false},{"date":"2021-12-31","value":-16787000000,"profit":false},{"date":"2022-12-31","value":-21597500000,"profit":false},{"date":"2023-12-31","value":-6128600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(235.26M)(281.58M)(167.87M)(215.97M)(61.29M)[{"date":"2019-12-31","value":-23525900000,"profit":false},{"date":"2020-12-31","value":-28158400000,"profit":false},{"date":"2021-12-31","value":-16787000000,"profit":false},{"date":"2022-12-31","value":-21597500000,"profit":false},{"date":"2023-12-31","value":-6128600000,"profit":false}]
EPS (Diluted)(1.60)(1.80)(1.05)(0.97)(0.38)[{"date":"2019-12-31","value":-160,"profit":false},{"date":"2020-12-31","value":-180,"profit":false},{"date":"2021-12-31","value":-105,"profit":false},{"date":"2022-12-31","value":-97,"profit":false},{"date":"2023-12-31","value":-38,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACAD
Cash Ratio 1.64
Current Ratio 2.29
Quick Ratio 2.11

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACAD
ROA (LTM) 8.72%
ROE (LTM) 27.36%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACAD
Debt Ratio Lower is generally better. Negative is bad. 0.41
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.59

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACAD
Trailing PE 23.59
Forward PE 25.38
P/S (TTM) 3.29
P/B 5.27
Price/FCF 48
EV/R 2.72
EV/Ebitda 20.27
PEG NM

FAQs

What is ACADIA Pharmaceuticals Inc share price today?

ACADIA Pharmaceuticals Inc (ACAD) share price today is $18.4

Can Indians buy ACADIA Pharmaceuticals Inc shares?

Yes, Indians can buy shares of ACADIA Pharmaceuticals Inc (ACAD) on Vested. To buy ACADIA Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACAD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ACADIA Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of ACADIA Pharmaceuticals Inc (ACAD) via the Vested app. You can start investing in ACADIA Pharmaceuticals Inc (ACAD) with a minimum investment of $1.

How to invest in ACADIA Pharmaceuticals Inc shares from India?

You can invest in shares of ACADIA Pharmaceuticals Inc (ACAD) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACAD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ACADIA Pharmaceuticals Inc shares
What is ACADIA Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of ACADIA Pharmaceuticals Inc (ACAD) is $26.83. The 52-week low price of ACADIA Pharmaceuticals Inc (ACAD) is $14.15.

What is ACADIA Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ACADIA Pharmaceuticals Inc (ACAD) is 23.4231

What is ACADIA Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ACADIA Pharmaceuticals Inc (ACAD) is 5.27

What is the Market Cap of ACADIA Pharmaceuticals Inc?

The market capitalization of ACADIA Pharmaceuticals Inc (ACAD) is $3.06B

What is ACADIA Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of ACADIA Pharmaceuticals Inc is ACAD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top